Publications Related to Workshop
Cherla A, Wagner AK, Wouters OJ, Woloshin S, Davis C, Mossialos E, Naci H. Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines. JAMA. 2025 Oct 28;334(16):1480-1482. doi: 10.1001/jama.2025.13917. PMID: 40900610; PMCID: PMC12409641.
Cherla A, Woloshin S, Wagner AK, Wouters OJ, Davis C, Mossialos E, Naci H. New Cancer Drug Approvals: Less Than Half Of Important Clinical Trial Uncertainties Reported By The FDA To Clinicians, 2019-22. Health Aff (Millwood). 2025 Jul;44(7):830-838. doi: 10.1377/hlthaff.2024.01134. PMID: 40623257.
Forrest R, Aggarwal A, Tregear M, et al. Patient Perspectives on Approval Speed vs Evidentiary Certainty in US Cancer Drug Approvals. JAMA Netw Open. 2026;9(6):e2617450. doi:10.1001/jamanetworkopen.2026.17450
- Invited Commentary on the above publication: Dusetzina SB, Jazowski SA. Resetting the Evidence Bar for New Anticancer Drug Approvals. JAMA Netw Open. 2026;9(6):e2617456. doi:10.1001/jamanetworkopen.2026.17456